
Annual report 2025
added 04-11-2026
Midatech Pharma plc Net Income 2011-2026 | MTP
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Midatech Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -5.46 M | -22.2 M | -10.1 M | -15 M | -16.1 M | -20.2 M | -10.1 M | -7.38 M | -4.08 M | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.08 M | -22.2 M | -12.3 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 335.82 | -1.06 % | $ 44 B | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.73 | 3.04 % | $ 8.97 B | ||
|
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-24.2 M | $ 7.39 | -15.45 % | $ 73 M | ||
|
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | ||
|
Burford Capital Limited
BUR
|
172 M | $ 4.83 | 2.44 % | $ 761 M | ||
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | ||
|
Cabaletta Bio
CABA
|
-168 M | $ 3.39 | 3.96 % | $ 341 M | ||
|
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 21.41 | 0.14 % | $ 1 B | ||
|
BioNTech SE
BNTX
|
10.3 B | $ 99.5 | 1.11 % | $ 27.2 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 3.09 | 1.31 % | $ 5.09 M | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-5.34 M | $ 1.54 | -1.6 % | $ 396 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.19 | 0.97 % | $ 448 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.5 | -2.34 % | $ 3.12 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | ||
|
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.47 | -1.01 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B | ||
|
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | ||
|
CNS Pharmaceuticals
CNSP
|
-15.9 M | $ 2.76 | 4.36 % | $ 1.22 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | ||
|
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | ||
|
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
-170 M | - | - | $ 1.41 B | ||
|
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 4.6 | -0.65 % | $ 310 B | ||
|
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | ||
|
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | ||
|
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K |